2005 related articles for article (PubMed ID: 24161419)
1. Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study.
Distler M; Pilarsky E; Kersting S; Grützmann R
Int J Surg; 2013; 11(10):1067-72. PubMed ID: 24161419
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the prognostic impact of pre- and post-operative CA19-9, SPan-1, and DUPAN-II levels in patients with pancreatic carcinoma.
Kondo N; Murakami Y; Uemura K; Nakagawa N; Takahashi S; Ohge H; Sueda T
Pancreatology; 2017; 17(1):95-102. PubMed ID: 27746094
[TBL] [Abstract][Full Text] [Related]
3. Postoperative carcinoembryonic antigen as a complementary tumor marker of carbohydrate antigen 19-9 in pancreatic ductal adenocarcinoma.
Kim J; Lee YS; Hwang IK; Kang BK; Cho JY; Yoon YS; Han HS; Hwang JH
J Korean Med Sci; 2015 Mar; 30(3):259-63. PubMed ID: 25729247
[TBL] [Abstract][Full Text] [Related]
4. Multivariate analysis of the prognostic value of CEA and CA 19-9 serum levels in colorectal cancer.
Reiter W; Stieber P; Reuter C; Nagel D; Lau-Werner U; Lamerz R
Anticancer Res; 2000; 20(6D):5195-8. PubMed ID: 11326694
[TBL] [Abstract][Full Text] [Related]
5. Predictive Early Recurrence Factors of Preoperative Clinicophysiological Findings in Pancreatic Cancer.
Suzuki S; Shimoda M; Shimazaki J; Maruyama T; Oshiro Y; Nishida K; Sahara Y; Nagakawa Y; Tsuchida A
Eur Surg Res; 2018; 59(5-6):329-338. PubMed ID: 30453288
[TBL] [Abstract][Full Text] [Related]
6. Serum HCG beta and CA 72-4 are stronger prognostic factors than CEA, CA 19-9 and CA 242 in pancreatic cancer.
Louhimo J; Alfthan H; Stenman UH; Haglund C
Oncology; 2004; 66(2):126-31. PubMed ID: 15138364
[TBL] [Abstract][Full Text] [Related]
7. Preoperative evaluation of pancreatic ductal adenocarcinoma with synchronous liver metastasis: Diagnosis and assessment of unresectability.
Shi HJ; Jin C; Fu DL
World J Gastroenterol; 2016 Dec; 22(45):10024-10037. PubMed ID: 28018110
[TBL] [Abstract][Full Text] [Related]
8. Preoperative serum carcinoembryonic antigen and carbohydrate antigen 19-9 levels for the evaluation of curability and resectability in patients with pancreatic adenocarcinoma.
Fujioka S; Misawa T; Okamoto T; Gocho T; Futagawa Y; Ishida Y; Yanaga K
J Hepatobiliary Pancreat Surg; 2007; 14(6):539-44. PubMed ID: 18040617
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of preoperative serum levels of CEA, CA 19-9 and CA 72-4 in gastric carcinoma.
Reiter W; Stieber P; Reuter C; Nagel D; Cramer C; Pahl H; Fateh-Moghadam A
Anticancer Res; 1997; 17(4B):2903-6. PubMed ID: 9329559
[TBL] [Abstract][Full Text] [Related]
10. Prognostic impact of postoperative serum CA 19-9 levels in patients with resectable pancreatic cancer.
Hata S; Sakamoto Y; Yamamoto Y; Nara S; Esaki M; Shimada K; Kosuge T
Ann Surg Oncol; 2012 Feb; 19(2):636-41. PubMed ID: 21863360
[TBL] [Abstract][Full Text] [Related]
11. Preoperative serum C-reactive protein levels and post-operative lymph node ratio are important predictors of survival after pancreaticoduodenectomy for pancreatic ductal adenocarcinoma.
Sanjay P; de Figueiredo RS; Leaver H; Ogston S; Kulli C; Polignano FM; Tait IS
JOP; 2012 Mar; 13(2):199-204. PubMed ID: 22406601
[TBL] [Abstract][Full Text] [Related]
12. Postoperative serum CEA and CA125 levels are supplementary to perioperative CA19-9 levels in predicting operative outcomes of pancreatic ductal adenocarcinoma.
Xu HX; Liu L; Xiang JF; Wang WQ; Qi ZH; Wu CT; Liu C; Long J; Xu J; Ni QX; Yu XJ
Surgery; 2017 Feb; 161(2):373-384. PubMed ID: 27838102
[TBL] [Abstract][Full Text] [Related]
13. Doublecortin and CaM kinase-like-1 as an independent prognostic factor in patients with resected pancreatic carcinoma.
Nishio K; Kimura K; Amano R; Nakata B; Yamazoe S; Ohira G; Miura K; Kametani N; Tanaka H; Muguruma K; Hirakawa K; Ohira M
World J Gastroenterol; 2017 Aug; 23(31):5764-5772. PubMed ID: 28883702
[TBL] [Abstract][Full Text] [Related]
14. Can preoperative CA19-9 and CEA levels predict the resectability of patients with pancreatic adenocarcinoma?
Kim YC; Kim HJ; Park JH; Park DI; Cho YK; Sohn CI; Jeon WK; Kim BI; Shin JH
J Gastroenterol Hepatol; 2009 Dec; 24(12):1869-75. PubMed ID: 19686409
[TBL] [Abstract][Full Text] [Related]
15. Combination of the serum carbohydrate antigen 19-9 and carcinoembryonic antigen is a simple and accurate predictor of mortality in pancreatic cancer patients.
Kanda M; Fujii T; Takami H; Suenaga M; Inokawa Y; Yamada S; Nakayama G; Sugimoto H; Koike M; Nomoto S; Kodera Y
Surg Today; 2014 Sep; 44(9):1692-701. PubMed ID: 24114022
[TBL] [Abstract][Full Text] [Related]
16. Elevated CEA and CA19-9 serum levels independently predict advanced pancreatic cancer at diagnosis.
van Manen L; Groen JV; Putter H; Vahrmeijer AL; Swijnenburg RJ; Bonsing BA; Mieog JSD
Biomarkers; 2020 Mar; 25(2):186-193. PubMed ID: 32009482
[No Abstract] [Full Text] [Related]
17. Preoperative serum levels of CEA and CA 19-9 and their prognostic significance in colorectal carcinoma.
Reiter W; Stieber P; Reuter C; Nagel D; Lau-Werner U; Pahl H; Fateh-Moghadam A
Anticancer Res; 1997; 17(4B):2935-8. PubMed ID: 9329568
[TBL] [Abstract][Full Text] [Related]
18. Conditional survival of pancreatic ductal adenocarcinoma in surgical and nonsurgical patients: a retrospective analysis report from a single institution in China.
Liao R; Yang J; Zhou BY; Li DW; Huang P; Luo SQ; Du CY
World J Surg Oncol; 2015 Jun; 13():196. PubMed ID: 26048469
[TBL] [Abstract][Full Text] [Related]
19. Preoperative serum CA19-9 and dissected peripancreatic tissue margin as determiners of long-term survival in pancreatic cancer.
Waraya M; Yamashita K; Katagiri H; Ishii K; Takahashi Y; Furuta K; Watanabe M
Ann Surg Oncol; 2009 May; 16(5):1231-40. PubMed ID: 19263172
[TBL] [Abstract][Full Text] [Related]
20. Serum Marker Score Based on Prognostic Nutrition Index, Carcinoembryonic Antigen, and Carbohydrate Antigen 19-9 Is Associated With Recurrence for Patients Undergoing Surgery for Pancreatic Ductal Adenocarcinoma.
Nakagawa S; Yamashita YI; Umezaki N; Yamao T; Okabe H; Imai K; Nitta H; Hashimoto D; Chikamoto A; Baba H
Pancreas; 2018 Oct; 47(9):1130-1134. PubMed ID: 30161074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]